Discussing the decentralization of manufacturing cell therapies

WEST WARWICK, Rhode Island
June, 2023

We are ardent believers in the future of decentralized manufacturing of cell therapies in highly-controlled, closed, automated systems such as those blood centers have been using for years to process blood and blood components supplies to hospitals every day. Indeed late last year we made a submission to the FDA outlining our position that the national footprint of blood centers local to the entire US healthcare system was perfectly and best positioned to provide the kind of footprint needed in a future in which decentralized manufacturing of cell-based therapies was possible and permitted. Even though we don’t believe that “decentralized” should be confused with “point-of-care”, here’s a great article discussing some key aspects around trend:


About Blood Centers of America
 Blood Centers of America (BCA) is a member-owned organization comprised of over 50 independent blood centers throughout the North America, representing nearly 40% of the U.S. blood supply. Along with their core business of providing a substantial portion of U.S. blood supply, other BCA member services include patient blood management, transfusion services, immunohematology testing, therapeutic apheresis and tissue and cord blood banking. In addition, BCA members provide a variety of human blood products, cells and tissues to the therapeutic, diagnostic and cell therapy industries.